University of Geneva: Brain Cancer - Immunotherapy First, Surgery Afterwards
September 02, 2026
September 02, 2026
GENEVA, Switzerland, Sept. 2 (TNSjou) -- The University of Geneva issued the following news release:
* * *
Brain cancer: Immunotherapy first, surgery afterwards
A team from UNIGE and HUG has shown that administering cell immunotherapy before surgery to remove a brain tumour is significantly more effective than administering it afterwards.
With survival at barely 5% at five years, glioblastoma remains one of the deadliest brain cancers. The firs . . .
* * *
Brain cancer: Immunotherapy first, surgery afterwards
A team from UNIGE and HUG has shown that administering cell immunotherapy before surgery to remove a brain tumour is significantly more effective than administering it afterwards.
With survival at barely 5% at five years, glioblastoma remains one of the deadliest brain cancers. The firs . . .